nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—UGT1A1—Naltrexone—alcohol dependence	0.176	0.323	CbGbCtD
Sorafenib—HTR2C—Citalopram—alcohol dependence	0.0725	0.133	CbGbCtD
Sorafenib—CYP3A5—Disulfiram—alcohol dependence	0.0498	0.0914	CbGbCtD
Sorafenib—CYP2B6—Citalopram—alcohol dependence	0.045	0.0827	CbGbCtD
Sorafenib—ABCB1—Naltrexone—alcohol dependence	0.0348	0.064	CbGbCtD
Sorafenib—CYP2C9—Disulfiram—alcohol dependence	0.0334	0.0613	CbGbCtD
Sorafenib—CYP2C19—Citalopram—alcohol dependence	0.0286	0.0525	CbGbCtD
Sorafenib—CYP1A2—Citalopram—alcohol dependence	0.0264	0.0485	CbGbCtD
Sorafenib—ABCB1—Citalopram—alcohol dependence	0.0231	0.0424	CbGbCtD
Sorafenib—CYP2D6—Citalopram—alcohol dependence	0.0217	0.0399	CbGbCtD
Sorafenib—CYP3A4—Disulfiram—alcohol dependence	0.0194	0.0356	CbGbCtD
Sorafenib—CYP3A4—Citalopram—alcohol dependence	0.0138	0.0254	CbGbCtD
Sorafenib—Folliculitis—Citalopram—alcohol dependence	0.00112	0.00646	CcSEcCtD
Sorafenib—Blood pressure increased—Naltrexone—alcohol dependence	0.00111	0.00641	CcSEcCtD
Sorafenib—Embolism—Citalopram—alcohol dependence	0.0011	0.00632	CcSEcCtD
Sorafenib—Hypothyroidism—Citalopram—alcohol dependence	0.0011	0.00632	CcSEcCtD
Sorafenib—Mouth ulceration—Acamprosate—alcohol dependence	0.00106	0.00612	CcSEcCtD
Sorafenib—Haemoglobin decreased—Citalopram—alcohol dependence	0.00102	0.0059	CcSEcCtD
Sorafenib—Eczema—Acamprosate—alcohol dependence	0.00095	0.00547	CcSEcCtD
Sorafenib—Renal failure acute—Acamprosate—alcohol dependence	0.000925	0.00532	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Acamprosate—alcohol dependence	0.000905	0.00521	CcSEcCtD
Sorafenib—Cardiac failure congestive—Naltrexone—alcohol dependence	0.000891	0.00513	CcSEcCtD
Sorafenib—Myocardial ischaemia—Citalopram—alcohol dependence	0.000877	0.00505	CcSEcCtD
Sorafenib—Cardiac failure—Acamprosate—alcohol dependence	0.000875	0.00504	CcSEcCtD
Sorafenib—Rhinorrhoea—Citalopram—alcohol dependence	0.000871	0.00501	CcSEcCtD
Sorafenib—Hyponatraemia—Acamprosate—alcohol dependence	0.000857	0.00494	CcSEcCtD
Sorafenib—Dysphonia—Citalopram—alcohol dependence	0.000857	0.00493	CcSEcCtD
Sorafenib—Endocrine disorder—Citalopram—alcohol dependence	0.000851	0.0049	CcSEcCtD
Sorafenib—Pain in extremity—Naltrexone—alcohol dependence	0.000808	0.00465	CcSEcCtD
Sorafenib—Rhabdomyolysis—Citalopram—alcohol dependence	0.000797	0.00459	CcSEcCtD
Sorafenib—Dry skin—Acamprosate—alcohol dependence	0.000783	0.00451	CcSEcCtD
Sorafenib—Bone disorder—Citalopram—alcohol dependence	0.000781	0.00449	CcSEcCtD
Sorafenib—Gastrooesophageal reflux disease—Citalopram—alcohol dependence	0.000781	0.00449	CcSEcCtD
Sorafenib—Breast disorder—Acamprosate—alcohol dependence	0.000772	0.00444	CcSEcCtD
Sorafenib—Hypocalcaemia—Citalopram—alcohol dependence	0.00077	0.00443	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Acamprosate—alcohol dependence	0.000769	0.00443	CcSEcCtD
Sorafenib—Glossitis—Citalopram—alcohol dependence	0.000765	0.00441	CcSEcCtD
Sorafenib—Drug interaction—Citalopram—alcohol dependence	0.00076	0.00438	CcSEcCtD
Sorafenib—Gastritis—Acamprosate—alcohol dependence	0.000756	0.00435	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Acamprosate—alcohol dependence	0.000753	0.00434	CcSEcCtD
Sorafenib—Dehydration—Naltrexone—alcohol dependence	0.000751	0.00433	CcSEcCtD
Sorafenib—Blood bilirubin increased—Citalopram—alcohol dependence	0.000746	0.00429	CcSEcCtD
Sorafenib—Dysphagia—Acamprosate—alcohol dependence	0.000738	0.00425	CcSEcCtD
Sorafenib—Abdominal pain upper—Naltrexone—alcohol dependence	0.000738	0.00425	CcSEcCtD
Sorafenib—Fatigue—Disulfiram—alcohol dependence	0.000735	0.00423	CcSEcCtD
Sorafenib—Pain—Disulfiram—alcohol dependence	0.000729	0.00419	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Naltrexone—alcohol dependence	0.000728	0.00419	CcSEcCtD
Sorafenib—Pancreatitis—Acamprosate—alcohol dependence	0.000724	0.00417	CcSEcCtD
Sorafenib—Nasopharyngitis—Naltrexone—alcohol dependence	0.000723	0.00416	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Naltrexone—alcohol dependence	0.000713	0.0041	CcSEcCtD
Sorafenib—Blood pressure increased—Citalopram—alcohol dependence	0.000705	0.00406	CcSEcCtD
Sorafenib—Influenza like illness—Citalopram—alcohol dependence	0.000685	0.00394	CcSEcCtD
Sorafenib—Erectile dysfunction—Acamprosate—alcohol dependence	0.00068	0.00391	CcSEcCtD
Sorafenib—Abdominal discomfort—Naltrexone—alcohol dependence	0.00067	0.00385	CcSEcCtD
Sorafenib—Weight decreased—Acamprosate—alcohol dependence	0.000668	0.00384	CcSEcCtD
Sorafenib—Neuropathy—Citalopram—alcohol dependence	0.000662	0.00381	CcSEcCtD
Sorafenib—Pneumonia—Acamprosate—alcohol dependence	0.000662	0.00381	CcSEcCtD
Sorafenib—Acute coronary syndrome—Acamprosate—alcohol dependence	0.000649	0.00373	CcSEcCtD
Sorafenib—Myocardial infarction—Acamprosate—alcohol dependence	0.000645	0.00371	CcSEcCtD
Sorafenib—Stomatitis—Acamprosate—alcohol dependence	0.000642	0.00369	CcSEcCtD
Sorafenib—Neoplasm—Citalopram—alcohol dependence	0.000638	0.00367	CcSEcCtD
Sorafenib—Mouth ulceration—Citalopram—alcohol dependence	0.000638	0.00367	CcSEcCtD
Sorafenib—Weight decreased—Naltrexone—alcohol dependence	0.000632	0.00364	CcSEcCtD
Sorafenib—Gynaecomastia—Citalopram—alcohol dependence	0.000631	0.00363	CcSEcCtD
Sorafenib—Pneumonia—Naltrexone—alcohol dependence	0.000626	0.0036	CcSEcCtD
Sorafenib—Infestation NOS—Naltrexone—alcohol dependence	0.000623	0.00358	CcSEcCtD
Sorafenib—Infestation—Naltrexone—alcohol dependence	0.000623	0.00358	CcSEcCtD
Sorafenib—Epistaxis—Acamprosate—alcohol dependence	0.000621	0.00357	CcSEcCtD
Sorafenib—Acute coronary syndrome—Naltrexone—alcohol dependence	0.000614	0.00353	CcSEcCtD
Sorafenib—Asthenia—Disulfiram—alcohol dependence	0.000611	0.00352	CcSEcCtD
Sorafenib—Myocardial infarction—Naltrexone—alcohol dependence	0.00061	0.00351	CcSEcCtD
Sorafenib—Haemoglobin—Acamprosate—alcohol dependence	0.000594	0.00342	CcSEcCtD
Sorafenib—Haemorrhage—Acamprosate—alcohol dependence	0.000591	0.0034	CcSEcCtD
Sorafenib—Hepatobiliary disease—Naltrexone—alcohol dependence	0.000589	0.00339	CcSEcCtD
Sorafenib—Epistaxis—Naltrexone—alcohol dependence	0.000587	0.00338	CcSEcCtD
Sorafenib—Hepatic failure—Citalopram—alcohol dependence	0.00057	0.00328	CcSEcCtD
Sorafenib—Eczema—Citalopram—alcohol dependence	0.00057	0.00328	CcSEcCtD
Sorafenib—Dizziness—Disulfiram—alcohol dependence	0.000563	0.00324	CcSEcCtD
Sorafenib—Renal failure acute—Citalopram—alcohol dependence	0.000555	0.00319	CcSEcCtD
Sorafenib—Tinnitus—Acamprosate—alcohol dependence	0.000551	0.00317	CcSEcCtD
Sorafenib—Connective tissue disorder—Naltrexone—alcohol dependence	0.000549	0.00316	CcSEcCtD
Sorafenib—Rash—Disulfiram—alcohol dependence	0.000537	0.00309	CcSEcCtD
Sorafenib—Headache—Disulfiram—alcohol dependence	0.000534	0.00307	CcSEcCtD
Sorafenib—Immune system disorder—Acamprosate—alcohol dependence	0.000534	0.00307	CcSEcCtD
Sorafenib—Cardiac failure—Citalopram—alcohol dependence	0.000525	0.00302	CcSEcCtD
Sorafenib—Alopecia—Acamprosate—alcohol dependence	0.000522	0.003	CcSEcCtD
Sorafenib—Tinnitus—Naltrexone—alcohol dependence	0.000521	0.003	CcSEcCtD
Sorafenib—Cardiac disorder—Naltrexone—alcohol dependence	0.000519	0.00299	CcSEcCtD
Sorafenib—Mental disorder—Acamprosate—alcohol dependence	0.000518	0.00298	CcSEcCtD
Sorafenib—Malnutrition—Acamprosate—alcohol dependence	0.000514	0.00296	CcSEcCtD
Sorafenib—Hyponatraemia—Citalopram—alcohol dependence	0.000514	0.00296	CcSEcCtD
Sorafenib—Pain in extremity—Citalopram—alcohol dependence	0.000512	0.00295	CcSEcCtD
Sorafenib—Angiopathy—Naltrexone—alcohol dependence	0.000507	0.00292	CcSEcCtD
Sorafenib—Immune system disorder—Naltrexone—alcohol dependence	0.000505	0.00291	CcSEcCtD
Sorafenib—Mediastinal disorder—Naltrexone—alcohol dependence	0.000504	0.0029	CcSEcCtD
Sorafenib—Dysgeusia—Acamprosate—alcohol dependence	0.000504	0.0029	CcSEcCtD
Sorafenib—Muscle spasms—Acamprosate—alcohol dependence	0.000494	0.00285	CcSEcCtD
Sorafenib—Alopecia—Naltrexone—alcohol dependence	0.000494	0.00284	CcSEcCtD
Sorafenib—Mental disorder—Naltrexone—alcohol dependence	0.00049	0.00282	CcSEcCtD
Sorafenib—Malnutrition—Naltrexone—alcohol dependence	0.000487	0.0028	CcSEcCtD
Sorafenib—Mood swings—Citalopram—alcohol dependence	0.000485	0.00279	CcSEcCtD
Sorafenib—Dysgeusia—Naltrexone—alcohol dependence	0.000477	0.00274	CcSEcCtD
Sorafenib—Dehydration—Citalopram—alcohol dependence	0.000476	0.00274	CcSEcCtD
Sorafenib—Anaemia—Acamprosate—alcohol dependence	0.000475	0.00274	CcSEcCtD
Sorafenib—Angioedema—Acamprosate—alcohol dependence	0.00047	0.0027	CcSEcCtD
Sorafenib—Dry skin—Citalopram—alcohol dependence	0.000469	0.0027	CcSEcCtD
Sorafenib—Muscle spasms—Naltrexone—alcohol dependence	0.000468	0.00269	CcSEcCtD
Sorafenib—Abdominal pain upper—Citalopram—alcohol dependence	0.000468	0.00269	CcSEcCtD
Sorafenib—Hypokalaemia—Citalopram—alcohol dependence	0.000466	0.00268	CcSEcCtD
Sorafenib—Breast disorder—Citalopram—alcohol dependence	0.000463	0.00266	CcSEcCtD
Sorafenib—Syncope—Acamprosate—alcohol dependence	0.000461	0.00265	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Citalopram—alcohol dependence	0.000461	0.00265	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Citalopram—alcohol dependence	0.000461	0.00265	CcSEcCtD
Sorafenib—Leukopenia—Acamprosate—alcohol dependence	0.00046	0.00265	CcSEcCtD
Sorafenib—Nasopharyngitis—Citalopram—alcohol dependence	0.000458	0.00264	CcSEcCtD
Sorafenib—Gastritis—Citalopram—alcohol dependence	0.000453	0.00261	CcSEcCtD
Sorafenib—Loss of consciousness—Acamprosate—alcohol dependence	0.000452	0.0026	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Citalopram—alcohol dependence	0.000452	0.0026	CcSEcCtD
Sorafenib—Cough—Acamprosate—alcohol dependence	0.000449	0.00258	CcSEcCtD
Sorafenib—Angioedema—Naltrexone—alcohol dependence	0.000445	0.00256	CcSEcCtD
Sorafenib—Hypertension—Acamprosate—alcohol dependence	0.000444	0.00256	CcSEcCtD
Sorafenib—Dysphagia—Citalopram—alcohol dependence	0.000443	0.00255	CcSEcCtD
Sorafenib—Myalgia—Acamprosate—alcohol dependence	0.000438	0.00252	CcSEcCtD
Sorafenib—Arthralgia—Acamprosate—alcohol dependence	0.000438	0.00252	CcSEcCtD
Sorafenib—Syncope—Naltrexone—alcohol dependence	0.000436	0.00251	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Acamprosate—alcohol dependence	0.000435	0.0025	CcSEcCtD
Sorafenib—Pancreatitis—Citalopram—alcohol dependence	0.000434	0.0025	CcSEcCtD
Sorafenib—Dry mouth—Acamprosate—alcohol dependence	0.000428	0.00246	CcSEcCtD
Sorafenib—Loss of consciousness—Naltrexone—alcohol dependence	0.000428	0.00246	CcSEcCtD
Sorafenib—Cough—Naltrexone—alcohol dependence	0.000425	0.00244	CcSEcCtD
Sorafenib—Abdominal discomfort—Citalopram—alcohol dependence	0.000424	0.00244	CcSEcCtD
Sorafenib—Hypertension—Naltrexone—alcohol dependence	0.00042	0.00242	CcSEcCtD
Sorafenib—Anaphylactic shock—Acamprosate—alcohol dependence	0.00042	0.00242	CcSEcCtD
Sorafenib—Infection—Acamprosate—alcohol dependence	0.000417	0.0024	CcSEcCtD
Sorafenib—Arthralgia—Naltrexone—alcohol dependence	0.000414	0.00238	CcSEcCtD
Sorafenib—Myalgia—Naltrexone—alcohol dependence	0.000414	0.00238	CcSEcCtD
Sorafenib—Shock—Acamprosate—alcohol dependence	0.000413	0.00238	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Naltrexone—alcohol dependence	0.000411	0.00237	CcSEcCtD
Sorafenib—Thrombocytopenia—Acamprosate—alcohol dependence	0.000411	0.00237	CcSEcCtD
Sorafenib—Skin disorder—Acamprosate—alcohol dependence	0.000408	0.00235	CcSEcCtD
Sorafenib—Erectile dysfunction—Citalopram—alcohol dependence	0.000408	0.00235	CcSEcCtD
Sorafenib—Dry mouth—Naltrexone—alcohol dependence	0.000405	0.00233	CcSEcCtD
Sorafenib—Weight decreased—Citalopram—alcohol dependence	0.0004	0.0023	CcSEcCtD
Sorafenib—Anorexia—Acamprosate—alcohol dependence	0.0004	0.0023	CcSEcCtD
Sorafenib—Anaphylactic shock—Naltrexone—alcohol dependence	0.000397	0.00229	CcSEcCtD
Sorafenib—Pneumonia—Citalopram—alcohol dependence	0.000397	0.00228	CcSEcCtD
Sorafenib—Infection—Naltrexone—alcohol dependence	0.000395	0.00227	CcSEcCtD
Sorafenib—Infestation—Citalopram—alcohol dependence	0.000395	0.00227	CcSEcCtD
Sorafenib—Infestation NOS—Citalopram—alcohol dependence	0.000395	0.00227	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Citalopram—alcohol dependence	0.000391	0.00225	CcSEcCtD
Sorafenib—Shock—Naltrexone—alcohol dependence	0.000391	0.00225	CcSEcCtD
Sorafenib—Nervous system disorder—Naltrexone—alcohol dependence	0.000389	0.00224	CcSEcCtD
Sorafenib—Acute coronary syndrome—Citalopram—alcohol dependence	0.000389	0.00224	CcSEcCtD
Sorafenib—Neuropathy peripheral—Citalopram—alcohol dependence	0.000387	0.00223	CcSEcCtD
Sorafenib—Myocardial infarction—Citalopram—alcohol dependence	0.000387	0.00223	CcSEcCtD
Sorafenib—Skin disorder—Naltrexone—alcohol dependence	0.000386	0.00222	CcSEcCtD
Sorafenib—Stomatitis—Citalopram—alcohol dependence	0.000385	0.00221	CcSEcCtD
Sorafenib—Jaundice—Citalopram—alcohol dependence	0.000385	0.00221	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Acamprosate—alcohol dependence	0.000382	0.0022	CcSEcCtD
Sorafenib—Anorexia—Naltrexone—alcohol dependence	0.000379	0.00218	CcSEcCtD
Sorafenib—Dyspnoea—Acamprosate—alcohol dependence	0.000374	0.00215	CcSEcCtD
Sorafenib—Hepatobiliary disease—Citalopram—alcohol dependence	0.000373	0.00215	CcSEcCtD
Sorafenib—Epistaxis—Citalopram—alcohol dependence	0.000372	0.00214	CcSEcCtD
Sorafenib—Dyspepsia—Acamprosate—alcohol dependence	0.000369	0.00213	CcSEcCtD
Sorafenib—Decreased appetite—Acamprosate—alcohol dependence	0.000365	0.0021	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Acamprosate—alcohol dependence	0.000362	0.00209	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Naltrexone—alcohol dependence	0.000362	0.00208	CcSEcCtD
Sorafenib—Pain—Acamprosate—alcohol dependence	0.000359	0.00207	CcSEcCtD
Sorafenib—Constipation—Acamprosate—alcohol dependence	0.000359	0.00207	CcSEcCtD
Sorafenib—Haemoglobin—Citalopram—alcohol dependence	0.000356	0.00205	CcSEcCtD
Sorafenib—Haemorrhage—Citalopram—alcohol dependence	0.000354	0.00204	CcSEcCtD
Sorafenib—Dyspnoea—Naltrexone—alcohol dependence	0.000354	0.00204	CcSEcCtD
Sorafenib—Urinary tract disorder—Citalopram—alcohol dependence	0.00035	0.00201	CcSEcCtD
Sorafenib—Connective tissue disorder—Citalopram—alcohol dependence	0.000348	0.002	CcSEcCtD
Sorafenib—Urethral disorder—Citalopram—alcohol dependence	0.000347	0.002	CcSEcCtD
Sorafenib—UGT1A9—liver—alcohol dependence	0.000346	0.00225	CbGeAlD
Sorafenib—Decreased appetite—Naltrexone—alcohol dependence	0.000345	0.00199	CcSEcCtD
Sorafenib—PDGFRB—adrenal cortex—alcohol dependence	0.000344	0.00223	CbGeAlD
Sorafenib—MAP3K19—brain—alcohol dependence	0.000344	0.00223	CbGeAlD
Sorafenib—Gastrointestinal pain—Acamprosate—alcohol dependence	0.000343	0.00198	CcSEcCtD
Sorafenib—MKNK2—endocrine gland—alcohol dependence	0.000343	0.00222	CbGeAlD
Sorafenib—Gastrointestinal disorder—Naltrexone—alcohol dependence	0.000343	0.00197	CcSEcCtD
Sorafenib—Fatigue—Naltrexone—alcohol dependence	0.000342	0.00197	CcSEcCtD
Sorafenib—FLT4—liver—alcohol dependence	0.000342	0.00222	CbGeAlD
Sorafenib—FLT1—blood—alcohol dependence	0.00034	0.0022	CbGeAlD
Sorafenib—Pain—Naltrexone—alcohol dependence	0.00034	0.00195	CcSEcCtD
Sorafenib—Constipation—Naltrexone—alcohol dependence	0.00034	0.00195	CcSEcCtD
Sorafenib—MKNK1—endocrine gland—alcohol dependence	0.000339	0.0022	CbGeAlD
Sorafenib—RAF1—blood—alcohol dependence	0.000338	0.00219	CbGeAlD
Sorafenib—STK10—digestive system—alcohol dependence	0.000338	0.00219	CbGeAlD
Sorafenib—MAP3K7—testis—alcohol dependence	0.000338	0.00219	CbGeAlD
Sorafenib—FGFR1—liver—alcohol dependence	0.000337	0.00219	CbGeAlD
Sorafenib—EPHB6—blood—alcohol dependence	0.000336	0.00218	CbGeAlD
Sorafenib—FLT1—midbrain—alcohol dependence	0.000335	0.00218	CbGeAlD
Sorafenib—Erythema multiforme—Citalopram—alcohol dependence	0.000335	0.00193	CcSEcCtD
Sorafenib—RET—endocrine gland—alcohol dependence	0.000335	0.00217	CbGeAlD
Sorafenib—PDGFRA—digestive system—alcohol dependence	0.000334	0.00217	CbGeAlD
Sorafenib—RAF1—midbrain—alcohol dependence	0.000333	0.00216	CbGeAlD
Sorafenib—Urticaria—Acamprosate—alcohol dependence	0.000333	0.00192	CcSEcCtD
Sorafenib—Abdominal pain—Acamprosate—alcohol dependence	0.000332	0.00191	CcSEcCtD
Sorafenib—Body temperature increased—Acamprosate—alcohol dependence	0.000332	0.00191	CcSEcCtD
Sorafenib—EPHB6—midbrain—alcohol dependence	0.000332	0.00215	CbGeAlD
Sorafenib—Tinnitus—Citalopram—alcohol dependence	0.00033	0.0019	CcSEcCtD
Sorafenib—FGFR1—cerebellum—alcohol dependence	0.000329	0.00214	CbGeAlD
Sorafenib—Flushing—Citalopram—alcohol dependence	0.000329	0.00189	CcSEcCtD
Sorafenib—Cardiac disorder—Citalopram—alcohol dependence	0.000329	0.00189	CcSEcCtD
Sorafenib—TIE1—brain—alcohol dependence	0.000328	0.00213	CbGeAlD
Sorafenib—MKNK2—testis—alcohol dependence	0.000327	0.00212	CbGeAlD
Sorafenib—Gastrointestinal pain—Naltrexone—alcohol dependence	0.000325	0.00187	CcSEcCtD
Sorafenib—HTR2C—brainstem—alcohol dependence	0.000325	0.00211	CbGeAlD
Sorafenib—MKNK1—testis—alcohol dependence	0.000323	0.00209	CbGeAlD
Sorafenib—KIT—cardiovascular system—alcohol dependence	0.000322	0.00209	CbGeAlD
Sorafenib—CSF1R—gonad—alcohol dependence	0.000322	0.00209	CbGeAlD
Sorafenib—STK10—blood—alcohol dependence	0.000322	0.00209	CbGeAlD
Sorafenib—Angiopathy—Citalopram—alcohol dependence	0.000321	0.00185	CcSEcCtD
Sorafenib—MKNK2—nervous system—alcohol dependence	0.000321	0.00208	CbGeAlD
Sorafenib—Immune system disorder—Citalopram—alcohol dependence	0.00032	0.00184	CcSEcCtD
Sorafenib—CYP3A7—endocrine gland—alcohol dependence	0.00032	0.00207	CbGeAlD
Sorafenib—Mediastinal disorder—Citalopram—alcohol dependence	0.000319	0.00184	CcSEcCtD
Sorafenib—MAP3K7—liver—alcohol dependence	0.000319	0.00207	CbGeAlD
Sorafenib—RET—testis—alcohol dependence	0.000319	0.00207	CbGeAlD
Sorafenib—UGT1A1—digestive system—alcohol dependence	0.000319	0.00207	CbGeAlD
Sorafenib—PDGFRA—blood—alcohol dependence	0.000318	0.00206	CbGeAlD
Sorafenib—MKNK1—nervous system—alcohol dependence	0.000317	0.00206	CbGeAlD
Sorafenib—Arrhythmia—Citalopram—alcohol dependence	0.000316	0.00182	CcSEcCtD
Sorafenib—Urticaria—Naltrexone—alcohol dependence	0.000316	0.00182	CcSEcCtD
Sorafenib—BRAF—brain—alcohol dependence	0.000315	0.00204	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—alcohol dependence	0.000314	0.00204	CbGeAlD
Sorafenib—Body temperature increased—Naltrexone—alcohol dependence	0.000314	0.00181	CcSEcCtD
Sorafenib—Abdominal pain—Naltrexone—alcohol dependence	0.000314	0.00181	CcSEcCtD
Sorafenib—HTR2C—forebrain—alcohol dependence	0.000313	0.00203	CbGeAlD
Sorafenib—RET—nervous system—alcohol dependence	0.000313	0.00203	CbGeAlD
Sorafenib—Alopecia—Citalopram—alcohol dependence	0.000313	0.0018	CcSEcCtD
Sorafenib—KIT—pancreas—alcohol dependence	0.000313	0.00203	CbGeAlD
Sorafenib—MAP3K7—cerebellum—alcohol dependence	0.000312	0.00202	CbGeAlD
Sorafenib—Mental disorder—Citalopram—alcohol dependence	0.00031	0.00179	CcSEcCtD
Sorafenib—RALBP1—endocrine gland—alcohol dependence	0.00031	0.00201	CbGeAlD
Sorafenib—Hypersensitivity—Acamprosate—alcohol dependence	0.000309	0.00178	CcSEcCtD
Sorafenib—MKNK2—liver—alcohol dependence	0.000309	0.00201	CbGeAlD
Sorafenib—MKNK2—central nervous system—alcohol dependence	0.000309	0.002	CbGeAlD
Sorafenib—Malnutrition—Citalopram—alcohol dependence	0.000308	0.00177	CcSEcCtD
Sorafenib—Erythema—Citalopram—alcohol dependence	0.000308	0.00177	CcSEcCtD
Sorafenib—PDGFRB—pancreas—alcohol dependence	0.000305	0.00198	CbGeAlD
Sorafenib—MKNK1—liver—alcohol dependence	0.000305	0.00198	CbGeAlD
Sorafenib—MKNK1—central nervous system—alcohol dependence	0.000305	0.00198	CbGeAlD
Sorafenib—UGT1A1—blood—alcohol dependence	0.000304	0.00197	CbGeAlD
Sorafenib—MKNK2—cerebellum—alcohol dependence	0.000302	0.00196	CbGeAlD
Sorafenib—Dysgeusia—Citalopram—alcohol dependence	0.000302	0.00174	CcSEcCtD
Sorafenib—RET—central nervous system—alcohol dependence	0.000301	0.00196	CbGeAlD
Sorafenib—KDR—digestive system—alcohol dependence	0.000301	0.00195	CbGeAlD
Sorafenib—Asthenia—Acamprosate—alcohol dependence	0.000301	0.00173	CcSEcCtD
Sorafenib—EPHX2—brain—alcohol dependence	0.000301	0.00195	CbGeAlD
Sorafenib—MKNK1—cerebellum—alcohol dependence	0.000298	0.00193	CbGeAlD
Sorafenib—Pruritus—Acamprosate—alcohol dependence	0.000297	0.00171	CcSEcCtD
Sorafenib—Muscle spasms—Citalopram—alcohol dependence	0.000296	0.00171	CcSEcCtD
Sorafenib—ABCC4—forebrain—alcohol dependence	0.000296	0.00192	CbGeAlD
Sorafenib—RALBP1—testis—alcohol dependence	0.000295	0.00192	CbGeAlD
Sorafenib—RET—cerebellum—alcohol dependence	0.000295	0.00191	CbGeAlD
Sorafenib—FLT1—endocrine gland—alcohol dependence	0.000295	0.00191	CbGeAlD
Sorafenib—HTR2B—forebrain—alcohol dependence	0.000294	0.00191	CbGeAlD
Sorafenib—CSF1R—digestive system—alcohol dependence	0.000294	0.00191	CbGeAlD
Sorafenib—RAF1—endocrine gland—alcohol dependence	0.000293	0.0019	CbGeAlD
Sorafenib—Hypersensitivity—Naltrexone—alcohol dependence	0.000293	0.00168	CcSEcCtD
Sorafenib—KIT—gonad—alcohol dependence	0.000292	0.00189	CbGeAlD
Sorafenib—RALBP1—nervous system—alcohol dependence	0.00029	0.00188	CbGeAlD
Sorafenib—CYP3A7—liver—alcohol dependence	0.000288	0.00187	CbGeAlD
Sorafenib—Diarrhoea—Acamprosate—alcohol dependence	0.000287	0.00165	CcSEcCtD
Sorafenib—KDR—blood—alcohol dependence	0.000287	0.00186	CbGeAlD
Sorafenib—MAP2K5—blood—alcohol dependence	0.000287	0.00186	CbGeAlD
Sorafenib—PDGFRB—gonad—alcohol dependence	0.000285	0.00185	CbGeAlD
Sorafenib—Anaemia—Citalopram—alcohol dependence	0.000285	0.00164	CcSEcCtD
Sorafenib—Asthenia—Naltrexone—alcohol dependence	0.000285	0.00164	CcSEcCtD
Sorafenib—MAP2K5—midbrain—alcohol dependence	0.000284	0.00184	CbGeAlD
Sorafenib—KDR—midbrain—alcohol dependence	0.000284	0.00184	CbGeAlD
Sorafenib—Angioedema—Citalopram—alcohol dependence	0.000282	0.00162	CcSEcCtD
Sorafenib—Pruritus—Naltrexone—alcohol dependence	0.000281	0.00162	CcSEcCtD
Sorafenib—FLT1—testis—alcohol dependence	0.000281	0.00182	CbGeAlD
Sorafenib—CSF1R—blood—alcohol dependence	0.00028	0.00182	CbGeAlD
Sorafenib—RAF1—testis—alcohol dependence	0.000279	0.00181	CbGeAlD
Sorafenib—RALBP1—liver—alcohol dependence	0.000279	0.00181	CbGeAlD
Sorafenib—RALBP1—central nervous system—alcohol dependence	0.000279	0.00181	CbGeAlD
Sorafenib—STK10—endocrine gland—alcohol dependence	0.000279	0.00181	CbGeAlD
Sorafenib—EPHB6—testis—alcohol dependence	0.000278	0.0018	CbGeAlD
Sorafenib—Dizziness—Acamprosate—alcohol dependence	0.000278	0.0016	CcSEcCtD
Sorafenib—CSF1R—midbrain—alcohol dependence	0.000277	0.00179	CbGeAlD
Sorafenib—Syncope—Citalopram—alcohol dependence	0.000277	0.00159	CcSEcCtD
Sorafenib—PDGFRA—endocrine gland—alcohol dependence	0.000276	0.00179	CbGeAlD
Sorafenib—Leukopenia—Citalopram—alcohol dependence	0.000276	0.00159	CcSEcCtD
Sorafenib—FLT1—nervous system—alcohol dependence	0.000276	0.00179	CbGeAlD
Sorafenib—RAF1—nervous system—alcohol dependence	0.000274	0.00178	CbGeAlD
Sorafenib—RALBP1—cerebellum—alcohol dependence	0.000273	0.00177	CbGeAlD
Sorafenib—HTR2B—adrenal cortex—alcohol dependence	0.000273	0.00177	CbGeAlD
Sorafenib—EPHB6—nervous system—alcohol dependence	0.000273	0.00177	CbGeAlD
Sorafenib—Diarrhoea—Naltrexone—alcohol dependence	0.000272	0.00156	CcSEcCtD
Sorafenib—FLT4—brain—alcohol dependence	0.000271	0.00176	CbGeAlD
Sorafenib—Loss of consciousness—Citalopram—alcohol dependence	0.000271	0.00156	CcSEcCtD
Sorafenib—Cough—Citalopram—alcohol dependence	0.000269	0.00155	CcSEcCtD
Sorafenib—FGFR1—brain—alcohol dependence	0.000267	0.00173	CbGeAlD
Sorafenib—KIT—digestive system—alcohol dependence	0.000267	0.00173	CbGeAlD
Sorafenib—Vomiting—Acamprosate—alcohol dependence	0.000267	0.00154	CcSEcCtD
Sorafenib—Hypertension—Citalopram—alcohol dependence	0.000266	0.00153	CcSEcCtD
Sorafenib—STK10—testis—alcohol dependence	0.000266	0.00172	CbGeAlD
Sorafenib—FLT1—liver—alcohol dependence	0.000266	0.00172	CbGeAlD
Sorafenib—FLT1—central nervous system—alcohol dependence	0.000265	0.00172	CbGeAlD
Sorafenib—Rash—Acamprosate—alcohol dependence	0.000265	0.00152	CcSEcCtD
Sorafenib—Dermatitis—Acamprosate—alcohol dependence	0.000264	0.00152	CcSEcCtD
Sorafenib—RAF1—liver—alcohol dependence	0.000264	0.00171	CbGeAlD
Sorafenib—RAF1—central nervous system—alcohol dependence	0.000264	0.00171	CbGeAlD
Sorafenib—UGT1A1—endocrine gland—alcohol dependence	0.000263	0.00171	CbGeAlD
Sorafenib—PDGFRA—testis—alcohol dependence	0.000263	0.00171	CbGeAlD
Sorafenib—Headache—Acamprosate—alcohol dependence	0.000263	0.00151	CcSEcCtD
Sorafenib—Dizziness—Naltrexone—alcohol dependence	0.000263	0.00151	CcSEcCtD
Sorafenib—Myalgia—Citalopram—alcohol dependence	0.000262	0.00151	CcSEcCtD
Sorafenib—Arthralgia—Citalopram—alcohol dependence	0.000262	0.00151	CcSEcCtD
Sorafenib—EPHB6—central nervous system—alcohol dependence	0.000262	0.0017	CbGeAlD
Sorafenib—STK10—nervous system—alcohol dependence	0.000261	0.00169	CbGeAlD
Sorafenib—PDGFRB—digestive system—alcohol dependence	0.000261	0.00169	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Citalopram—alcohol dependence	0.000261	0.0015	CcSEcCtD
Sorafenib—FLT1—cerebellum—alcohol dependence	0.00026	0.00168	CbGeAlD
Sorafenib—PDGFRA—nervous system—alcohol dependence	0.000258	0.00168	CbGeAlD
Sorafenib—RAF1—cerebellum—alcohol dependence	0.000258	0.00167	CbGeAlD
Sorafenib—Dry mouth—Citalopram—alcohol dependence	0.000257	0.00148	CcSEcCtD
Sorafenib—EPHB6—cerebellum—alcohol dependence	0.000257	0.00166	CbGeAlD
Sorafenib—KIT—blood—alcohol dependence	0.000254	0.00165	CbGeAlD
Sorafenib—MAP3K7—brain—alcohol dependence	0.000253	0.00164	CbGeAlD
Sorafenib—Vomiting—Naltrexone—alcohol dependence	0.000253	0.00145	CcSEcCtD
Sorafenib—Anaphylactic shock—Citalopram—alcohol dependence	0.000252	0.00145	CcSEcCtD
Sorafenib—STK10—liver—alcohol dependence	0.000251	0.00163	CbGeAlD
Sorafenib—STK10—central nervous system—alcohol dependence	0.000251	0.00163	CbGeAlD
Sorafenib—KIT—midbrain—alcohol dependence	0.000251	0.00163	CbGeAlD
Sorafenib—Rash—Naltrexone—alcohol dependence	0.00025	0.00144	CcSEcCtD
Sorafenib—Dermatitis—Naltrexone—alcohol dependence	0.00025	0.00144	CcSEcCtD
Sorafenib—Infection—Citalopram—alcohol dependence	0.00025	0.00144	CcSEcCtD
Sorafenib—Nausea—Acamprosate—alcohol dependence	0.000249	0.00144	CcSEcCtD
Sorafenib—MAP2K5—endocrine gland—alcohol dependence	0.000249	0.00162	CbGeAlD
Sorafenib—KDR—endocrine gland—alcohol dependence	0.000249	0.00162	CbGeAlD
Sorafenib—PDGFRA—liver—alcohol dependence	0.000249	0.00161	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—alcohol dependence	0.000249	0.00161	CbGeAlD
Sorafenib—Headache—Naltrexone—alcohol dependence	0.000249	0.00143	CcSEcCtD
Sorafenib—PDGFRA—central nervous system—alcohol dependence	0.000249	0.00161	CbGeAlD
Sorafenib—PDGFRB—blood—alcohol dependence	0.000249	0.00161	CbGeAlD
Sorafenib—Shock—Citalopram—alcohol dependence	0.000248	0.00142	CcSEcCtD
Sorafenib—Nervous system disorder—Citalopram—alcohol dependence	0.000247	0.00142	CcSEcCtD
Sorafenib—Thrombocytopenia—Citalopram—alcohol dependence	0.000246	0.00142	CcSEcCtD
Sorafenib—STK10—cerebellum—alcohol dependence	0.000246	0.00159	CbGeAlD
Sorafenib—PDGFRB—midbrain—alcohol dependence	0.000245	0.00159	CbGeAlD
Sorafenib—MKNK2—brain—alcohol dependence	0.000245	0.00159	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—alcohol dependence	0.000245	0.00159	CbGeAlD
Sorafenib—Skin disorder—Citalopram—alcohol dependence	0.000244	0.00141	CcSEcCtD
Sorafenib—ABCC4—pancreas—alcohol dependence	0.000243	0.00158	CbGeAlD
Sorafenib—PDGFRA—cerebellum—alcohol dependence	0.000243	0.00158	CbGeAlD
Sorafenib—CSF1R—endocrine gland—alcohol dependence	0.000243	0.00158	CbGeAlD
Sorafenib—MKNK1—brain—alcohol dependence	0.000242	0.00157	CbGeAlD
Sorafenib—Anorexia—Citalopram—alcohol dependence	0.00024	0.00138	CcSEcCtD
Sorafenib—RET—brain—alcohol dependence	0.000239	0.00155	CbGeAlD
Sorafenib—MAP2K5—testis—alcohol dependence	0.000238	0.00154	CbGeAlD
Sorafenib—KDR—testis—alcohol dependence	0.000238	0.00154	CbGeAlD
Sorafenib—UGT1A1—liver—alcohol dependence	0.000237	0.00154	CbGeAlD
Sorafenib—Nausea—Naltrexone—alcohol dependence	0.000236	0.00136	CcSEcCtD
Sorafenib—KDR—nervous system—alcohol dependence	0.000233	0.00151	CbGeAlD
Sorafenib—MAP2K5—nervous system—alcohol dependence	0.000233	0.00151	CbGeAlD
Sorafenib—CSF1R—testis—alcohol dependence	0.000232	0.0015	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Citalopram—alcohol dependence	0.000229	0.00132	CcSEcCtD
Sorafenib—CSF1R—nervous system—alcohol dependence	0.000228	0.00148	CbGeAlD
Sorafenib—KDR—liver—alcohol dependence	0.000225	0.00146	CbGeAlD
Sorafenib—MAP2K5—liver—alcohol dependence	0.000225	0.00146	CbGeAlD
Sorafenib—MAP2K5—central nervous system—alcohol dependence	0.000224	0.00146	CbGeAlD
Sorafenib—KDR—central nervous system—alcohol dependence	0.000224	0.00146	CbGeAlD
Sorafenib—Dyspnoea—Citalopram—alcohol dependence	0.000224	0.00129	CcSEcCtD
Sorafenib—RALBP1—brain—alcohol dependence	0.000222	0.00144	CbGeAlD
Sorafenib—Dyspepsia—Citalopram—alcohol dependence	0.000222	0.00127	CcSEcCtD
Sorafenib—KIT—endocrine gland—alcohol dependence	0.000221	0.00143	CbGeAlD
Sorafenib—MAP2K5—cerebellum—alcohol dependence	0.000219	0.00142	CbGeAlD
Sorafenib—KDR—cerebellum—alcohol dependence	0.000219	0.00142	CbGeAlD
Sorafenib—CSF1R—liver—alcohol dependence	0.000219	0.00142	CbGeAlD
Sorafenib—CSF1R—central nervous system—alcohol dependence	0.000219	0.00142	CbGeAlD
Sorafenib—Decreased appetite—Citalopram—alcohol dependence	0.000219	0.00126	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Citalopram—alcohol dependence	0.000217	0.00125	CcSEcCtD
Sorafenib—Fatigue—Citalopram—alcohol dependence	0.000217	0.00125	CcSEcCtD
Sorafenib—PDGFRB—endocrine gland—alcohol dependence	0.000216	0.0014	CbGeAlD
Sorafenib—Pain—Citalopram—alcohol dependence	0.000215	0.00124	CcSEcCtD
Sorafenib—Constipation—Citalopram—alcohol dependence	0.000215	0.00124	CcSEcCtD
Sorafenib—CSF1R—cerebellum—alcohol dependence	0.000214	0.00139	CbGeAlD
Sorafenib—FLT1—brain—alcohol dependence	0.000211	0.00137	CbGeAlD
Sorafenib—KIT—testis—alcohol dependence	0.00021	0.00137	CbGeAlD
Sorafenib—RAF1—brain—alcohol dependence	0.00021	0.00136	CbGeAlD
Sorafenib—EPHB6—brain—alcohol dependence	0.000208	0.00135	CbGeAlD
Sorafenib—ABCC4—digestive system—alcohol dependence	0.000208	0.00135	CbGeAlD
Sorafenib—HTR2C—midbrain—alcohol dependence	0.000207	0.00134	CbGeAlD
Sorafenib—HTR2B—digestive system—alcohol dependence	0.000207	0.00134	CbGeAlD
Sorafenib—KIT—nervous system—alcohol dependence	0.000207	0.00134	CbGeAlD
Sorafenib—Gastrointestinal pain—Citalopram—alcohol dependence	0.000206	0.00118	CcSEcCtD
Sorafenib—PDGFRB—testis—alcohol dependence	0.000206	0.00133	CbGeAlD
Sorafenib—PDGFRB—nervous system—alcohol dependence	0.000202	0.00131	CbGeAlD
Sorafenib—ABCC2—digestive system—alcohol dependence	0.000201	0.0013	CbGeAlD
Sorafenib—Urticaria—Citalopram—alcohol dependence	0.0002	0.00115	CcSEcCtD
Sorafenib—STK10—brain—alcohol dependence	0.0002	0.00129	CbGeAlD
Sorafenib—KIT—liver—alcohol dependence	0.000199	0.00129	CbGeAlD
Sorafenib—Body temperature increased—Citalopram—alcohol dependence	0.000199	0.00114	CcSEcCtD
Sorafenib—Abdominal pain—Citalopram—alcohol dependence	0.000199	0.00114	CcSEcCtD
Sorafenib—KIT—central nervous system—alcohol dependence	0.000199	0.00129	CbGeAlD
Sorafenib—ABCC4—blood—alcohol dependence	0.000198	0.00128	CbGeAlD
Sorafenib—PDGFRA—brain—alcohol dependence	0.000198	0.00128	CbGeAlD
Sorafenib—HTR2B—blood—alcohol dependence	0.000197	0.00128	CbGeAlD
Sorafenib—KIT—cerebellum—alcohol dependence	0.000194	0.00126	CbGeAlD
Sorafenib—PDGFRB—liver—alcohol dependence	0.000194	0.00126	CbGeAlD
Sorafenib—PDGFRB—central nervous system—alcohol dependence	0.000194	0.00126	CbGeAlD
Sorafenib—ABCG2—adrenal cortex—alcohol dependence	0.000194	0.00126	CbGeAlD
Sorafenib—ABCC2—blood—alcohol dependence	0.000192	0.00124	CbGeAlD
Sorafenib—PDGFRB—cerebellum—alcohol dependence	0.00019	0.00123	CbGeAlD
Sorafenib—Hypersensitivity—Citalopram—alcohol dependence	0.000185	0.00107	CcSEcCtD
Sorafenib—Asthenia—Citalopram—alcohol dependence	0.000181	0.00104	CcSEcCtD
Sorafenib—CYP2B6—adrenal cortex—alcohol dependence	0.000179	0.00116	CbGeAlD
Sorafenib—MAP2K5—brain—alcohol dependence	0.000178	0.00116	CbGeAlD
Sorafenib—KDR—brain—alcohol dependence	0.000178	0.00116	CbGeAlD
Sorafenib—Pruritus—Citalopram—alcohol dependence	0.000178	0.00102	CcSEcCtD
Sorafenib—CSF1R—brain—alcohol dependence	0.000174	0.00113	CbGeAlD
Sorafenib—CYP2C19—digestive system—alcohol dependence	0.000173	0.00112	CbGeAlD
Sorafenib—Diarrhoea—Citalopram—alcohol dependence	0.000172	0.000991	CcSEcCtD
Sorafenib—ABCC4—endocrine gland—alcohol dependence	0.000172	0.00111	CbGeAlD
Sorafenib—HTR2C—nervous system—alcohol dependence	0.00017	0.0011	CbGeAlD
Sorafenib—Dizziness—Citalopram—alcohol dependence	0.000166	0.000958	CcSEcCtD
Sorafenib—ABCC2—endocrine gland—alcohol dependence	0.000166	0.00108	CbGeAlD
Sorafenib—CYP2C19—blood—alcohol dependence	0.000165	0.00107	CbGeAlD
Sorafenib—HTR2C—central nervous system—alcohol dependence	0.000164	0.00106	CbGeAlD
Sorafenib—ABCC4—testis—alcohol dependence	0.000164	0.00106	CbGeAlD
Sorafenib—CYP2B6—cardiovascular system—alcohol dependence	0.000163	0.00106	CbGeAlD
Sorafenib—CYP2C9—cardiovascular system—alcohol dependence	0.000161	0.00105	CbGeAlD
Sorafenib—ABCC4—nervous system—alcohol dependence	0.000161	0.00104	CbGeAlD
Sorafenib—Vomiting—Citalopram—alcohol dependence	0.00016	0.000921	CcSEcCtD
Sorafenib—HTR2B—nervous system—alcohol dependence	0.00016	0.00104	CbGeAlD
Sorafenib—CYP3A5—pancreas—alcohol dependence	0.000159	0.00103	CbGeAlD
Sorafenib—Rash—Citalopram—alcohol dependence	0.000159	0.000913	CcSEcCtD
Sorafenib—Dermatitis—Citalopram—alcohol dependence	0.000159	0.000912	CcSEcCtD
Sorafenib—ABCC2—testis—alcohol dependence	0.000158	0.00103	CbGeAlD
Sorafenib—KIT—brain—alcohol dependence	0.000158	0.00102	CbGeAlD
Sorafenib—Headache—Citalopram—alcohol dependence	0.000158	0.000907	CcSEcCtD
Sorafenib—ABCC4—liver—alcohol dependence	0.000155	0.001	CbGeAlD
Sorafenib—ABCC4—central nervous system—alcohol dependence	0.000155	0.001	CbGeAlD
Sorafenib—PDGFRB—brain—alcohol dependence	0.000154	0.001	CbGeAlD
Sorafenib—HTR2B—central nervous system—alcohol dependence	0.000154	0.000998	CbGeAlD
Sorafenib—ABCC2—liver—alcohol dependence	0.00015	0.000971	CbGeAlD
Sorafenib—Nausea—Citalopram—alcohol dependence	0.000149	0.00086	CcSEcCtD
Sorafenib—CYP2D6—brainstem—alcohol dependence	0.000148	0.000962	CbGeAlD
Sorafenib—CYP2B6—gonad—alcohol dependence	0.000148	0.000959	CbGeAlD
Sorafenib—CYP2C8—blood—alcohol dependence	0.000144	0.000932	CbGeAlD
Sorafenib—CYP2D6—forebrain—alcohol dependence	0.000143	0.000929	CbGeAlD
Sorafenib—CYP2C19—endocrine gland—alcohol dependence	0.000143	0.000926	CbGeAlD
Sorafenib—CYP1A2—digestive system—alcohol dependence	0.000141	0.000915	CbGeAlD
Sorafenib—ABCG2—blood—alcohol dependence	0.00014	0.000906	CbGeAlD
Sorafenib—ABCG2—midbrain—alcohol dependence	0.000138	0.000895	CbGeAlD
Sorafenib—CYP3A5—digestive system—alcohol dependence	0.000136	0.000883	CbGeAlD
Sorafenib—CYP2B6—digestive system—alcohol dependence	0.000135	0.000877	CbGeAlD
Sorafenib—CYP1A2—blood—alcohol dependence	0.000134	0.000872	CbGeAlD
Sorafenib—CYP2C9—digestive system—alcohol dependence	0.000134	0.000869	CbGeAlD
Sorafenib—HTR2C—brain—alcohol dependence	0.00013	0.000843	CbGeAlD
Sorafenib—CYP3A5—blood—alcohol dependence	0.00013	0.000841	CbGeAlD
Sorafenib—CYP2B6—blood—alcohol dependence	0.000129	0.000836	CbGeAlD
Sorafenib—CYP2C19—liver—alcohol dependence	0.000129	0.000835	CbGeAlD
Sorafenib—CYP2C9—blood—alcohol dependence	0.000128	0.000828	CbGeAlD
Sorafenib—CYP2C8—endocrine gland—alcohol dependence	0.000125	0.000808	CbGeAlD
Sorafenib—ABCC4—brain—alcohol dependence	0.000123	0.000796	CbGeAlD
Sorafenib—HTR2B—brain—alcohol dependence	0.000122	0.000792	CbGeAlD
Sorafenib—CYP2C8—testis—alcohol dependence	0.000119	0.000771	CbGeAlD
Sorafenib—CYP1A2—endocrine gland—alcohol dependence	0.000117	0.000756	CbGeAlD
Sorafenib—ABCG2—testis—alcohol dependence	0.000116	0.000749	CbGeAlD
Sorafenib—CYP3A5—endocrine gland—alcohol dependence	0.000112	0.000729	CbGeAlD
Sorafenib—CYP2C8—liver—alcohol dependence	0.000112	0.000729	CbGeAlD
Sorafenib—CYP2B6—endocrine gland—alcohol dependence	0.000112	0.000725	CbGeAlD
Sorafenib—CYP2C9—endocrine gland—alcohol dependence	0.000111	0.000718	CbGeAlD
Sorafenib—ABCG2—liver—alcohol dependence	0.000109	0.000708	CbGeAlD
Sorafenib—ABCG2—cerebellum—alcohol dependence	0.000107	0.000692	CbGeAlD
Sorafenib—CYP2B6—testis—alcohol dependence	0.000107	0.000691	CbGeAlD
Sorafenib—CYP1A2—liver—alcohol dependence	0.000105	0.000682	CbGeAlD
Sorafenib—CYP2B6—nervous system—alcohol dependence	0.000105	0.000679	CbGeAlD
Sorafenib—ABCB1—forebrain—alcohol dependence	0.000103	0.000668	CbGeAlD
Sorafenib—CYP3A4—digestive system—alcohol dependence	0.000102	0.000662	CbGeAlD
Sorafenib—CYP3A5—liver—alcohol dependence	0.000101	0.000658	CbGeAlD
Sorafenib—CYP2B6—liver—alcohol dependence	0.000101	0.000654	CbGeAlD
Sorafenib—CYP2B6—central nervous system—alcohol dependence	0.000101	0.000653	CbGeAlD
Sorafenib—CYP2D6—digestive system—alcohol dependence	0.000101	0.000652	CbGeAlD
Sorafenib—CYP2C9—liver—alcohol dependence	9.98e-05	0.000647	CbGeAlD
Sorafenib—CYP3A4—blood—alcohol dependence	9.73e-05	0.000631	CbGeAlD
Sorafenib—CYP2D6—blood—alcohol dependence	9.58e-05	0.000621	CbGeAlD
Sorafenib—ABCB1—adrenal cortex—alcohol dependence	9.54e-05	0.000619	CbGeAlD
Sorafenib—CYP2C8—brain—alcohol dependence	8.92e-05	0.000578	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—alcohol dependence	8.71e-05	0.000565	CbGeAlD
Sorafenib—ABCG2—brain—alcohol dependence	8.67e-05	0.000562	CbGeAlD
Sorafenib—ABCB1—pancreas—alcohol dependence	8.47e-05	0.000549	CbGeAlD
Sorafenib—CYP3A4—endocrine gland—alcohol dependence	8.44e-05	0.000547	CbGeAlD
Sorafenib—CYP2D6—endocrine gland—alcohol dependence	8.31e-05	0.000539	CbGeAlD
Sorafenib—CYP2B6—brain—alcohol dependence	8e-05	0.000519	CbGeAlD
Sorafenib—CYP2D6—testis—alcohol dependence	7.92e-05	0.000514	CbGeAlD
Sorafenib—ABCB1—gonad—alcohol dependence	7.91e-05	0.000513	CbGeAlD
Sorafenib—CYP3A4—nervous system—alcohol dependence	7.9e-05	0.000512	CbGeAlD
Sorafenib—CYP2D6—nervous system—alcohol dependence	7.77e-05	0.000504	CbGeAlD
Sorafenib—CYP3A4—liver—alcohol dependence	7.61e-05	0.000494	CbGeAlD
Sorafenib—CYP3A4—central nervous system—alcohol dependence	7.61e-05	0.000493	CbGeAlD
Sorafenib—CYP2D6—liver—alcohol dependence	7.49e-05	0.000486	CbGeAlD
Sorafenib—CYP2D6—central nervous system—alcohol dependence	7.48e-05	0.000485	CbGeAlD
Sorafenib—CYP2D6—cerebellum—alcohol dependence	7.32e-05	0.000474	CbGeAlD
Sorafenib—ABCB1—digestive system—alcohol dependence	7.23e-05	0.000469	CbGeAlD
Sorafenib—ABCB1—blood—alcohol dependence	6.89e-05	0.000447	CbGeAlD
Sorafenib—ABCB1—midbrain—alcohol dependence	6.8e-05	0.000441	CbGeAlD
Sorafenib—ABCB1—endocrine gland—alcohol dependence	5.97e-05	0.000387	CbGeAlD
Sorafenib—CYP2D6—brain—alcohol dependence	5.94e-05	0.000385	CbGeAlD
Sorafenib—ABCB1—testis—alcohol dependence	5.7e-05	0.00037	CbGeAlD
Sorafenib—ABCB1—nervous system—alcohol dependence	5.59e-05	0.000363	CbGeAlD
Sorafenib—ABCB1—liver—alcohol dependence	5.39e-05	0.000349	CbGeAlD
Sorafenib—ABCB1—central nervous system—alcohol dependence	5.38e-05	0.000349	CbGeAlD
Sorafenib—ABCB1—cerebellum—alcohol dependence	5.26e-05	0.000341	CbGeAlD
Sorafenib—ABCB1—brain—alcohol dependence	4.27e-05	0.000277	CbGeAlD
Sorafenib—RAF1—Signaling Pathways—NPY—alcohol dependence	1.49e-05	0.000117	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HTR2A—alcohol dependence	1.49e-05	0.000116	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—EP300—alcohol dependence	1.48e-05	0.000116	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD2—alcohol dependence	1.46e-05	0.000115	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HTR7—alcohol dependence	1.46e-05	0.000115	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD2—alcohol dependence	1.46e-05	0.000114	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HTR7—alcohol dependence	1.46e-05	0.000114	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	1.46e-05	0.000114	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—EP300—alcohol dependence	1.44e-05	0.000113	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AVP—alcohol dependence	1.44e-05	0.000113	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AVP—alcohol dependence	1.44e-05	0.000113	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CRH—alcohol dependence	1.44e-05	0.000113	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR1B—alcohol dependence	1.44e-05	0.000113	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—EP300—alcohol dependence	1.44e-05	0.000113	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADH6—alcohol dependence	1.44e-05	0.000113	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC6A3—alcohol dependence	1.43e-05	0.000112	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADH7—alcohol dependence	1.43e-05	0.000112	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HTR2A—alcohol dependence	1.43e-05	0.000112	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AVP—alcohol dependence	1.42e-05	0.000112	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD4—alcohol dependence	1.41e-05	0.000111	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ADH1B—alcohol dependence	1.41e-05	0.00011	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—OPRM1—alcohol dependence	1.4e-05	0.00011	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADH7—alcohol dependence	1.4e-05	0.000109	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HTR2A—alcohol dependence	1.39e-05	0.000109	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HTR2A—alcohol dependence	1.39e-05	0.000109	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—GGT1—alcohol dependence	1.38e-05	0.000108	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—GOT1—alcohol dependence	1.38e-05	0.000108	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—GOT1—alcohol dependence	1.38e-05	0.000108	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—GGT1—alcohol dependence	1.38e-05	0.000108	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MAOB—alcohol dependence	1.38e-05	0.000108	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GGT2—alcohol dependence	1.37e-05	0.000107	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GOT2—alcohol dependence	1.36e-05	0.000106	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CNR1—alcohol dependence	1.35e-05	0.000106	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD4—alcohol dependence	1.34e-05	0.000105	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GOT2—alcohol dependence	1.34e-05	0.000105	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MAOB—alcohol dependence	1.34e-05	0.000105	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GGT2—alcohol dependence	1.34e-05	0.000105	CbGpPWpGaD
Sorafenib—CYP3A4—Biological oxidations—POMC—alcohol dependence	1.33e-05	0.000104	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	1.33e-05	0.000104	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—HTR2A—alcohol dependence	1.32e-05	0.000103	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—alcohol dependence	1.32e-05	0.000103	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADH7—alcohol dependence	1.32e-05	0.000103	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD2—alcohol dependence	1.31e-05	0.000103	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HTR7—alcohol dependence	1.31e-05	0.000103	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADH4—alcohol dependence	1.31e-05	0.000103	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—EP300—alcohol dependence	1.31e-05	0.000102	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—POMC—alcohol dependence	1.31e-05	0.000102	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADH7—alcohol dependence	1.3e-05	0.000102	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AVP—alcohol dependence	1.3e-05	0.000102	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AVP—alcohol dependence	1.3e-05	0.000102	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—EP300—alcohol dependence	1.29e-05	0.000101	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NPY—alcohol dependence	1.29e-05	0.000101	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CNR1—alcohol dependence	1.28e-05	0.000101	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—EP300—alcohol dependence	1.28e-05	0.0001	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CYP2E1—alcohol dependence	1.28e-05	9.99e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CYP2E1—alcohol dependence	1.26e-05	9.91e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GGT2—alcohol dependence	1.26e-05	9.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD4—alcohol dependence	1.26e-05	9.85e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADH1B—alcohol dependence	1.25e-05	9.83e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD2—alcohol dependence	1.25e-05	9.82e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HTR7—alcohol dependence	1.25e-05	9.82e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GGT2—alcohol dependence	1.25e-05	9.8e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR1B—alcohol dependence	1.24e-05	9.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CRH—alcohol dependence	1.24e-05	9.73e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—EP300—alcohol dependence	1.24e-05	9.7e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—MAOA—alcohol dependence	1.24e-05	9.69e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—MAOA—alcohol dependence	1.24e-05	9.69e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AVP—alcohol dependence	1.23e-05	9.64e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—EP300—alcohol dependence	1.23e-05	9.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AVP—alcohol dependence	1.23e-05	9.62e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADH1B—alcohol dependence	1.22e-05	9.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CNR1—alcohol dependence	1.2e-05	9.4e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	1.2e-05	9.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HTR2A—alcohol dependence	1.2e-05	9.39e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HTR2A—alcohol dependence	1.2e-05	9.38e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADH1A—alcohol dependence	1.19e-05	9.32e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—AVP—alcohol dependence	1.19e-05	9.3e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—POMC—alcohol dependence	1.19e-05	9.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HTR2A—alcohol dependence	1.19e-05	9.29e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GGT1—alcohol dependence	1.17e-05	9.18e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GOT1—alcohol dependence	1.17e-05	9.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD2—alcohol dependence	1.17e-05	9.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR7—alcohol dependence	1.17e-05	9.18e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALDH2—alcohol dependence	1.17e-05	9.16e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MAOB—alcohol dependence	1.16e-05	9.12e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GGT1—alcohol dependence	1.16e-05	9.1e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GOT1—alcohol dependence	1.16e-05	9.1e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—EP300—alcohol dependence	1.15e-05	9.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADH1B—alcohol dependence	1.15e-05	9.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADH1B—alcohol dependence	1.14e-05	8.96e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALDH2—alcohol dependence	1.14e-05	8.96e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—POMC—alcohol dependence	1.14e-05	8.94e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—alcohol dependence	1.13e-05	8.89e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADH7—alcohol dependence	1.11e-05	8.73e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—POMC—alcohol dependence	1.11e-05	8.71e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—POMC—alcohol dependence	1.11e-05	8.69e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EP300—alcohol dependence	1.11e-05	8.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AVP—alcohol dependence	1.11e-05	8.67e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD4—alcohol dependence	1.08e-05	8.5e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HTR2A—alcohol dependence	1.08e-05	8.45e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HTR2A—alcohol dependence	1.08e-05	8.45e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT2—alcohol dependence	1.07e-05	8.37e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AVP—alcohol dependence	1.05e-05	8.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—POMC—alcohol dependence	1.05e-05	8.26e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MAOA—alcohol dependence	1.05e-05	8.22e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MAOA—alcohol dependence	1.04e-05	8.15e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MAOB—alcohol dependence	1.04e-05	8.14e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CNR1—alcohol dependence	1.04e-05	8.12e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HTR2A—alcohol dependence	1.02e-05	8.02e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HTR2A—alcohol dependence	1.02e-05	8e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MAOB—alcohol dependence	1.01e-05	7.95e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADH4—alcohol dependence	1.01e-05	7.93e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD2—alcohol dependence	1.01e-05	7.92e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR7—alcohol dependence	1.01e-05	7.92e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GOT2—alcohol dependence	9.94e-06	7.79e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALDH2—alcohol dependence	9.9e-06	7.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AVP—alcohol dependence	9.85e-06	7.72e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EP300—alcohol dependence	9.8e-06	7.68e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADH1B—alcohol dependence	9.77e-06	7.66e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GOT2—alcohol dependence	9.72e-06	7.62e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—POMC—alcohol dependence	9.57e-06	7.5e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MAOB—alcohol dependence	9.56e-06	7.49e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—POMC—alcohol dependence	9.56e-06	7.49e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	9.52e-06	7.46e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MAOB—alcohol dependence	9.48e-06	7.43e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—POMC—alcohol dependence	9.47e-06	7.42e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP2E1—alcohol dependence	9.35e-06	7.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HTR2A—alcohol dependence	9.2e-06	7.21e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP2E1—alcohol dependence	9.14e-06	7.16e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EP300—alcohol dependence	8.97e-06	7.03e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EP300—alcohol dependence	8.84e-06	6.93e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EP300—alcohol dependence	8.84e-06	6.93e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALDH2—alcohol dependence	8.84e-06	6.93e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HTR2A—alcohol dependence	8.77e-06	6.88e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALDH2—alcohol dependence	8.63e-06	6.76e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—POMC—alcohol dependence	8.62e-06	6.75e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—POMC—alcohol dependence	8.62e-06	6.75e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADH7—alcohol dependence	8.6e-06	6.74e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GGT1—alcohol dependence	8.58e-06	6.73e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GOT1—alcohol dependence	8.58e-06	6.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AVP—alcohol dependence	8.51e-06	6.67e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	8.5e-06	6.66e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GOT2—alcohol dependence	8.42e-06	6.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EP300—alcohol dependence	8.39e-06	6.57e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GOT1—alcohol dependence	8.39e-06	6.57e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GGT1—alcohol dependence	8.39e-06	6.57e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EP300—alcohol dependence	8.37e-06	6.56e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT2—alcohol dependence	8.25e-06	6.46e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR2A—alcohol dependence	8.2e-06	6.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—POMC—alcohol dependence	8.18e-06	6.41e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EP300—alcohol dependence	8.16e-06	6.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—POMC—alcohol dependence	8.16e-06	6.39e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALDH2—alcohol dependence	8.13e-06	6.37e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MAOB—alcohol dependence	8.1e-06	6.35e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALDH2—alcohol dependence	8.06e-06	6.31e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—POMC—alcohol dependence	8.05e-06	6.31e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—POMC—alcohol dependence	8.05e-06	6.31e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP2E1—alcohol dependence	7.91e-06	6.2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	7.75e-06	6.07e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EP300—alcohol dependence	7.75e-06	6.07e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EP300—alcohol dependence	7.73e-06	6.05e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MAOA—alcohol dependence	7.69e-06	6.03e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EP300—alcohol dependence	7.56e-06	5.93e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADH1B—alcohol dependence	7.54e-06	5.91e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EP300—alcohol dependence	7.54e-06	5.91e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MAOA—alcohol dependence	7.52e-06	5.89e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GOT2—alcohol dependence	7.51e-06	5.89e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EP300—alcohol dependence	7.37e-06	5.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—POMC—alcohol dependence	7.35e-06	5.76e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GOT2—alcohol dependence	7.33e-06	5.75e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GGT1—alcohol dependence	7.27e-06	5.69e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GOT1—alcohol dependence	7.27e-06	5.69e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR2A—alcohol dependence	7.08e-06	5.55e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP2E1—alcohol dependence	7.06e-06	5.54e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—POMC—alcohol dependence	7.01e-06	5.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EP300—alcohol dependence	6.96e-06	5.45e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GOT2—alcohol dependence	6.91e-06	5.42e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP2E1—alcohol dependence	6.9e-06	5.4e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALDH2—alcohol dependence	6.89e-06	5.4e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GOT2—alcohol dependence	6.85e-06	5.37e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—POMC—alcohol dependence	6.83e-06	5.35e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—POMC—alcohol dependence	6.77e-06	5.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EP300—alcohol dependence	6.72e-06	5.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—alcohol dependence	6.62e-06	5.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—POMC—alcohol dependence	6.55e-06	5.13e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MAOA—alcohol dependence	6.51e-06	5.1e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP2E1—alcohol dependence	6.5e-06	5.09e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GGT1—alcohol dependence	6.49e-06	5.08e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GOT1—alcohol dependence	6.49e-06	5.08e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP2E1—alcohol dependence	6.44e-06	5.05e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EP300—alcohol dependence	6.34e-06	4.97e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GOT1—alcohol dependence	6.33e-06	4.96e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GGT1—alcohol dependence	6.33e-06	4.96e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	6.32e-06	4.95e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EP300—alcohol dependence	6.28e-06	4.92e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MAOB—alcohol dependence	6.25e-06	4.9e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EP300—alcohol dependence	6.2e-06	4.86e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GOT1—alcohol dependence	5.97e-06	4.68e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GGT1—alcohol dependence	5.97e-06	4.68e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GGT1—alcohol dependence	5.91e-06	4.63e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GOT1—alcohol dependence	5.91e-06	4.63e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT2—alcohol dependence	5.85e-06	4.59e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MAOA—alcohol dependence	5.81e-06	4.56e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—alcohol dependence	5.72e-06	4.48e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—alcohol dependence	5.72e-06	4.48e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MAOA—alcohol dependence	5.67e-06	4.45e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—alcohol dependence	5.65e-06	4.43e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	5.64e-06	4.42e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2E1—alcohol dependence	5.5e-06	4.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—alcohol dependence	5.42e-06	4.25e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—alcohol dependence	5.41e-06	4.24e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MAOA—alcohol dependence	5.35e-06	4.19e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—alcohol dependence	5.34e-06	4.19e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—alcohol dependence	5.34e-06	4.19e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALDH2—alcohol dependence	5.31e-06	4.16e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MAOA—alcohol dependence	5.3e-06	4.15e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	5.14e-06	4.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT1—alcohol dependence	5.05e-06	3.96e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT1—alcohol dependence	5.05e-06	3.96e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—alcohol dependence	5.01e-06	3.92e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—alcohol dependence	4.89e-06	3.84e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—alcohol dependence	4.87e-06	3.82e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—alcohol dependence	4.65e-06	3.64e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—alcohol dependence	4.53e-06	3.55e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MAOA—alcohol dependence	4.53e-06	3.55e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT2—alcohol dependence	4.52e-06	3.54e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—alcohol dependence	4.49e-06	3.52e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—alcohol dependence	4.39e-06	3.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—alcohol dependence	4.34e-06	3.4e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2E1—alcohol dependence	4.25e-06	3.33e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—alcohol dependence	4.24e-06	3.32e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT1—alcohol dependence	3.9e-06	3.06e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—alcohol dependence	3.9e-06	3.06e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—alcohol dependence	3.78e-06	2.97e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—alcohol dependence	3.75e-06	2.94e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—alcohol dependence	3.69e-06	2.89e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MAOA—alcohol dependence	3.5e-06	2.74e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—alcohol dependence	3.48e-06	2.73e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—alcohol dependence	3.45e-06	2.7e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—alcohol dependence	3.32e-06	2.6e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—alcohol dependence	3.25e-06	2.54e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—alcohol dependence	2.95e-06	2.31e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—alcohol dependence	2.81e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—alcohol dependence	2.51e-06	1.97e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—alcohol dependence	2.45e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—alcohol dependence	2.31e-06	1.81e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—alcohol dependence	2.29e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—alcohol dependence	2.28e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—alcohol dependence	1.96e-06	1.53e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—alcohol dependence	1.51e-06	1.18e-05	CbGpPWpGaD
